Company intelligence / Profile preview

Genetic Immunity

Budapest, Not specified, Hungarygeneticimmunity.hu ↗

Ownership: Private
Development stage: Phase 3

Overview

DermaVir, their lead product, has completed three clinical trials in the EU and US showing safety comparable to placebo, with four sequential patch treatments reducing HIV infected cells in the blood within 24 weeks.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Plasmid DNA-based therapeutic vaccinesNanomedicinesImmunotherapeutic biologic drugs
Industry: Biotech

Drug pipeline

1 asset

DermaVir

Beyond the preview

Go deeper on Genetic Immunity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genetic Immunity.

Explore the full profile